Area of research
Oncology · Pathology and Forensic Medicine
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Viral-associated cancers and disorders, Hematopoietic Stem Cell Transplantation, and Chronic Lymphocytic Leukemia Research.
NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025
TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers
Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101
NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide
Positron Emission Tomography–Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial
PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001
NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016
Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2015
Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage
A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS
Non-Hodgkin’s Lymphomas, Version 4.2014
Central Nervous System Cancers, Version 2.2014
Non-Hodgkin’s Lymphomas, Version 2.2014
Non-Hodgkin’s Lymphomas, Version 1.2013